The Role and Molecular Mechanism of E4BP4 in Pathological Cardiac Hypertrophy via Targeting TRAIL

Pathological cardiac hypertrophy (PCH) leads to heart failure. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a multifunctional cytokine, affects cardiovascular diseases. E4-binding protein 4 (E4BP4), implicated in cardiac stress, reportedly suppresses TRAIL. However, their role in PCH remains unclear. This study aims to investigate the role of E4BP4 in PCH and its underlying mechanism. Transverse aortic constriction (TAC) was used to induce PCH in mice. Echocardiography assessed cardiac function at 4, 6, 8, and 12 weeks post-surgery. Masson staining, immunofluorescence, qRT-PCR, and western blot were used to evaluate myocardial hypertrophy, fibrosis, and expression of E4BP4, TRAIL, and related receptors. Angiotensin II (Ang II)-induced hypertrophy was established in primary mouse cardiomyocytes. Cells were transfected with E4BP4 silencing or overexpression vectors. qRT-PCR, western blot, ELISA, phalloidin staining, and luciferase reporter assays measured E4BP4, TRAIL, receptors, hypertrophy/apoptosis markers, cell size, and E4BP4-TRAIL promoter binding. In hypertrophic mice, left ventricular ejection fraction and fractional shortening decreased, while left ventricular end-systolic diameter and mass increased, accompanied by aggravated myocardial fibrosis and abnormal hypertrophy markers. Ang II-induced cardiomyocytes showed increased cell area and abnormal expression of E4BP4, TRAIL, hypertrophy markers, and apoptosis-related proteins. Silencing E4BP4 exacerbated these changes, whereas overexpression reversed them. Luciferase assay confirmed that E4BP4 directly inhibited TRAIL promoter activity. In conclusion, E4BP4 mitigates hypertrophy and apoptosis by inhibiting TRAIL promoter activity and regulating TRAIL and its receptors, offering a potential therapeutic target for PCH.

Authors

Institutions

Publication Details

Journal
The Kaohsiung Journal of Medical Sciences
Published
2026-11-18
DOI
https://doi.org/10.1002/kjm2.70323
Primary Topic
Cardiac Fibrosis and Remodeling
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The Role and Molecular Mechanism of E4BP4 in Pathological Cardiac Hypertrophy via Targeting TRAIL

Derong Huang, Qing Wen, Ke Lin, Hang Hu
The Kaohsiung Journal of Medical Sciences
Cardiac Fibrosis and Remodeling
article

The Role and Molecular Mechanism of E4BP4 in Pathological Cardiac Hypertrophy via Targeting TRAIL

Derong Huang, Qing Wen, Ke Lin, Hang Hu
article en

Abstract

Pathological cardiac hypertrophy (PCH) leads to heart failure. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a multifunctional cytokine, affects cardiovascular diseases. E4-binding protein 4 (E4BP4), implicated in cardiac stress, reportedly suppresses TRAIL. However, their role in PCH remains unclear. This study aims to investigate the role of E4BP4 in PCH and its underlying mechanism. Transverse aortic constriction (TAC) was used to induce PCH in mice. Echocardiography assessed cardiac function at 4, 6, 8, and 12 weeks post-surgery. Masson staining, immunofluorescence, qRT-PCR, and western blot were used to evaluate myocardial hypertrophy, fibrosis, and expression of E4BP4, TRAIL, and related receptors. Angiotensin II (Ang II)-induced hypertrophy was established in primary mouse cardiomyocytes. Cells were transfected with E4BP4 silencing or overexpression vectors. qRT-PCR, western blot, ELISA, phalloidin staining, and luciferase reporter assays measured E4BP4, TRAIL, receptors, hypertrophy/apoptosis markers, cell size, and E4BP4-TRAIL promoter binding. In hypertrophic mice, left ventricular ejection fraction and fractional shortening decreased, while left ventricular end-systolic diameter and mass increased, accompanied by aggravated myocardial fibrosis and abnormal hypertrophy markers. Ang II-induced cardiomyocytes showed increased cell area and abnormal expression of E4BP4, TRAIL, hypertrophy markers, and apoptosis-related proteins. Silencing E4BP4 exacerbated these changes, whereas overexpression reversed them. Luciferase assay confirmed that E4BP4 directly inhibited TRAIL promoter activity. In conclusion, E4BP4 mitigates hypertrophy and apoptosis by inhibiting TRAIL promoter activity and regulating TRAIL and its receptors, offering a potential therapeutic target for PCH.

The Kaohsiung Journal of Medical Sciences
Zunyi Medical University (CN), Affiliated Hospital of Zunyi Medical College (CN)
Good health and well-being
Cardiac Fibrosis and Remodeling
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon